Protective live oral brucellosis vaccines stimulate Th1 and Th17 cell responses

Infection and Immunity

Volumn 79, Issue 10, 2011, Pages 4165-4174

  Clapp, Beata ^a   Skyberg, Jerod A ^a   Yang, Xinghong ^a   Thornburg, Theresa ^a   Walters, Nancy ^a   Pascual, W pascual ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUCELLA VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRUCELLA ABORTUS; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DELETION; HUMORAL IMMUNITY; IMMUNIZATION; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH17 CELL;

ADMINISTRATION, ORAL; ANIMALS; BRUCELLA MELITENSIS; BRUCELLA VACCINE; BRUCELLOSIS; FEMALE; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; TH1 CELLS; TH17 CELLS; VACCINATION; VACCINES, ATTENUATED;

EID: 80855127652     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05080-11     Document Type: Article

References (61)

1. Alcantara, R. B., R. D. A. Read, M. W. Valderas, T. D. Brown, and R. M. Roop. 2004. Intact purine biosynthesis pathways are required for wild-type virulence of Brucella abortus 2308 in the BALB/c mice model. Infect. Immun. 72:4911-4917.
2. Allen, C. A., L. G. Adams, and T. A. Ficht. 1998. Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival. Infect. Immun. 66:1008-1016.
3. Al-Tawfiq, J. A. 2008. Therapeutic options for human brucellosis. Expert Rev. Anti Infect. Ther. 6:109-120.
4. Alton, G. G. 1987. Control of Brucella melitensis infection in sheep and goats-a review. Trop. Anim. Health Prod. 19:65-74.
5. Alton, G. G., and W. Elberg. 1967. Rev. 1 Brucella melitensis vaccine. A review of ten years of study. Vet. Bull. 37:793-800.
6. Andoh, A., et al. 2005. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129:969-984.
7. Ariza, J., et al. 1995. Characteristics of and risk factors for relapse of brucellosis in humans. Clin. Infect. Dis. 20:1241-1249.
8. Ashford, D. A., et al. 2004. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 22:3435-3439.
9. Blasco, J. M., and R. Diza. 1993. Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342:805.
10. Chomel, B. B., et al. 1994. Changing trends in the epidemiology of human brucellosis in California from 1973 to 1992: a shift toward foodborne transmission. J. Infect. Dis. 170:1216-1223.
11. Chowdhury, M. I., A. Sheikh, and F. Quadri. 2009. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Vaccine 8:1643-1652.
12. Corbel, M. 1997. Brucellosis: an overview. Emerg. Infect. Dis. 3:213-221.
13. Curtis, M. M., and S. S. Way. 2009. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2:177-185.
14. Delpino, M. V., et al. 2007. A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice. Infect. Immun. 75:299-305.
15. Dhiman, R., et al. 2009. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J. Immunol. 183:6639-6645.
16. + T cells in vivo. Infect. Immun. 78:168-176.
17. Ficht, T. A. 2002. Discovery of Brucella virulence mechanisms using mutational analysis. Vet. Microbiol. 90:311-315.
18. Ficht, T. A., M. M. Kahl-McDonagh, A. M. Arenas-Gamboa, and A. C. Rice-Ficht. 2009. Brucellosis: the case for live, attenuated vaccines. Vaccine 27(Suppl. 4):40-43.
19. Franco, M. P., M. Mulder, R. H. Gilman, and H. L. Smits. 2007. Human brucellosis. Lancet Infect. Dis. 7:775-786.
20. Galen, J. E., et al. 2009. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol. Cell Biol. 87:400-412.
21. Godfroid, J., et al. 2005. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been re-emerging zoonosis. Vet. Res. 36:313-326.
22. Gorvel, J. P. 2008. Brucella: a Mr "Hide" converted into Dr Jekyll. Microbes Infect. 10:1010-1013.
23. Hedayatizadeh-Omran, A., A. Rafiei, M. Hajilooi, and M. Haghshenas. 2010. Interferon-γ low producer genotype +5644 over presented in patients with focal brucellosis. Pak. J. Biol. Sci. 13:1036-1041.
24. Hong, P. C., R. M. Tsolis, and T. A. Ficht. 2000. Identification of genes required for chronic persistence of Brucella abortus in mice. Infect. Immun. 62:4102-4107.
25. Hoover, D. L., et al. 1999. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201 (16MδpurEK). Infect. Immun. 67:5877-5884.
26. Ikeuchi, H., et al. 2005. Expression of IL-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52:1037-1046.
27. Infante-Duarte, C., H. F. Horton, M. C. Byrne, and T. Kamradt. 2000. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165:6107-6115.
28. Izadjoo, M. J., A. K. Bhattacharjee, C. M. Paranavitana, T. L. Hadfield, and D. L. Hoover. 2004. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infect. Immun. 72:4031-4039.
29. Jain, S. K. 2009. M-01ZH09, an oral live attenuated Salmonella enterica serovar Typhi vaccine for the prevention of typhoid fever. BMC Biol. 11:565-571.
30. Kahl-McDonagh, M. M., and T. A. Ficht. 2006. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect. Immun. 7:4048-4057.
31. Kerem, E., O. Diav, P. Navon, and D. Branski. 1994. Pleural fluid characteristics in pulmonary brucellosis. Thorax 49:89-90.
32. Kim, S., K. Watanabe, T. Shirahata, and M. Watarai. 2004. Zinc uptake system (δznuA locus) of Brucella abortus is essential for intracellular survival and virulence in mice. J. Vet. Med. Sci. 66:1059-1063.
33. Langrish, C. L., et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233-240.
34. Levine, M. M. 2010. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from live cholera vaccine. BMC Biol. 8:129-139.
35. Lubani, M. M., et al. 1989. Pulmonary brucellosis. Q. J. Med. 71:319-324.
36. Lulu, A. R., et al. 1988. Human brucellosis in Kuwait: a prospective study of 400 cases. Q. J. Med. 66:39-54.
37. Mann, B. J., and N. M. Ark. 2009. Rationally designed tularemia vaccines. Expert Rev. Vaccines 8:877-885.
38. Monreal, D., et al. 2003. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect. Immun. 71:3261-3271.
39. Moriyon, I., et al. 2004. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet. Res. 35:1-38.
40. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171:6173-6177.
41. Noviello, S., et al. 2004. Laboratory-acquired brucellosis. Emerg. Infect. Dis. 10:1848-1850.
42. Olsen, S. C., B. Bricker, M. V. Palmer, A. E. Jensen, and N. F. Cheville. 1999. Responses of cattle to two dosages of Brucella abortus strain RB51: serology, clearance and efficacy. Res. Vet. Sci. 66:101-105.
43. Ooi, J. D., A. R. Kitching, and S. R. Holdsworth. 2010. Review: T helper 17 cells: their role in glomerulonephritis. Nephrology 5:513-521.
44. Oyston, P. C. 2009. Francisella tularensis vaccines. Vaccine 27(Suppl.4):48-51.
45. Pappas, G., P. Papadimitriou, N. Akritidis, L. Christou, and E. V. Tsianos. 2006. The new global map of human brucellosis. Lancet Infect. Dis. 6:91-99.
46. Paranavitana, C., E. Zelazowska, L. DaSilva, P. R. Pittman, and M. Nikolich. 2010. Th17 cytokines in recall responses against Francisella tularensis in humans. J. Interferon Cytokine Res. 7:471-476.
47. Pascual, D. W., T. Trunkle, and J. Sura. 2002. Fimbriated Salmonella enterica serovar Typhimurium abates the initial inflammatory responses by macrophages. Infect. Immun. 70:4273-4281.
48. Pasquali, P., A. Rosanna, C. Pistoia, P. Petrucci, and F. Ciuchini. 2003. Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infect. Immun. 5:2326-2330.
49. Pasquevich, K. A., et al. 2011. An oral vaccine based on U-Omp 19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice. PLoS One 6:e16203.
50. Perkins, S. D., S. J. Smither, and H. S. Atkins. 2010. Towards a Brucella vaccine for humans. FEMS Microbiol. Rev. 34:379-394.
51. Pontes, D. S., et al. 2003. Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J. Drug Target. 11:489-493.
52. Rafiei, A., et al. 2006. Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. J. Infect. 53:315-324.
53. Roth, F., et al. 2003. Human health benefits from livestock vaccination for brucellosis: case study. Bull. World Health Organ. 81:867-876.
54. Rynda, A., M. Maddaloni, J. Ochoa-Repáraz, G. Callis, and D. W. Pascual. 2010. IL-28 supplants requirement for T reg cells in protein σ1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE). PLoS One 5:e8720.
55. + T cell subset contribute to the human anti-mycobacterial immune response. J. Immunol. 3:1962-1970.
56. Sonnenberg, G. F., and D. B. Weiner. 2009. Manipulation of Th17 responses in pulmonary immunity and disease through vaccination. Hum. Vaccine 8:510-519.
57. Walker, K. B., et al. 2010. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 28:2259-2270.
58. Wallach, J. C., M. C. Ferrero, M. V. Delpino, C. A. Fossati, and P. C. Baldi. 2008. Occupational infection due to Brucella abortus S19 among workers involved in vaccine production in Argentina. Clin. Microbiol. Infect. 14:805- 807.
59. Wang, X., D. M. Hone, A. Haddad, M. T. Shata, and D. W. Pascual. 2003. M cell DNA vaccination for CTL immunity to HIV. J. Immunol. 171:4717-4725.
60. Yang, X., T. Becker, S. M. Jun, N. Walters, and D. W. Pascual. 2006. Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infect. Immun. 74:3874-3879.
61. Young, E. J. 1983. Human brucellosis. Rev. Infect. Dis. 5:821-842.